ArticleLife (Basel, Switzerland)2025
The Functional Ingredients of the Combined Extract of Mulberry Leaves and Butterfly Pea Flowers Improve Insomnia, Anxiolytic, Memory-Enhancing, and Antidepressant-like Activities in Stress-Exposed Rats.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Functional Ingredient Derived From a Mixture of Mulberry (Oxidative medicine and cellular longevity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
At present, a novel herbal regimen targeting anti-insomnia, anti-anxiety, cognitive performance, and anti-depression effects is required due to the limitations of the current therapy. Based on the crucial role of oxidative stress in the pathophysiology of stress-related brain disorders, it was hypothesized that the functional ingredient derived from mulberry leaves and butterfly pea flowers, which exhibits potent antioxidant activity, should protect against the disorders just mentioned. Male Wistar rats (180-200 g) were orally administered at doses of 125, 250, and 500 mg/kg BW once daily, 45 min before exposure to a 6-h immobilization stress for 14 days. Behavioral assessments, including sleep, anxiety, spatial memory, and depression, were assessed every 7 days. At the end of the study, corticosterone levels, oxidative stress markers, neurotransmitters, IL-6, BDNF, and neuron density in the prefrontal cortex and hippocampus were measured. The functional ingredients demonstrated anti-insomnia, anxiolytic, memory-enhancing, and antidepressant properties. It also increased neuron density and BDNF and activity of SOD and CAT enzymes, whereas corticosterone, GABA-T, AChE, MAO, IL-6, and MDA levels were reduced. A potential regimen targeting showed the benefits of anti-insomnia, anxiolytic, memory-enhancing, and antidepressant properties. However, further studies regarding the precise underlying mechanism and a clinical trial are essentially required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.